DRUG manufacturing giant, Pfizer, today announced that an early analysis of its coronavirus vaccine trial has suggested the vaccine was robustly effective in preventing COVID-19.
Disclosing this today, Pfizer, which developed the vaccine with the German drug maker BioNTech, gave little details of its clinical trial, the first formal review of the data by an outside panel of experts could provide.
According to the company, the analysis found that the vaccine was more than 90 per cent effective in preventing the disease among trial volunteers who had no evidence of prior coronavirus infection.
“If the results hold up, that level of protection would put it on par with highly effective childhood vaccines for diseases such as measles. No serious safety concerns have been observed,” the company said.
Source says Pfizer plans to ask the Food and Drug Administration for Emergency authorisation of the two-dose vaccine later this month, after it has collected the recommended two months of safety data.
“By the end of the year, it will have manufactured enough doses to immunise 15 to 20 million people,” company executives said.
Further information reveals that the vaccine could get the mortality rate down to extremely low levels within a few months with targeted vaccinations of vulnerable groups.